Executive Summary
A decade of TAVR explant data from a single high-volume center is the most consequential read of the day: operative mortality reached 22.2% for early explants and 15.8% for late explants, climbing to 41.2% in high-risk reoperations — a sobering counterweight as ESC 2025 leans further into TAVI-first for patients ≥70 and ACC/AHA still draws the SAVR line at 65. A National Inpatient Sample analysis ties post-procedural delirium to a 27.7-fold mortality signal after TTVR and 4.5-fold after TAVR, while the first-in-man EVOQUE-after-Cardioband case shows what salvage tricuspid replacement looks like in ARVC. Together, these data tighten the case for careful patient selection in younger TAVI candidates and erase any remaining complacency about who tolerates a transcatheter explant when the valve fails.
- TAVR explant 3-year survival was 65.8% in lower-risk reoperations vs 45.3% in high-risk — durability planning at the index procedure is no longer optional (Cardiovasc Revasc Med).
- Delirium hit 4.4% of TTVR and 2.8% of TAVR cases, with adjusted in-hospital mortality ORs of 27.7 and 4.5 respectively (Cath Cardiovasc Interv).
- Self-expanding TAVR for non-calcified AR achieved ≤mild residual AR in all 25 patients at 12 months but required bailout balloon-expandable implants in 20% (Cardiovasc Revasc Med).
- Leadless pacemakers after TAVR cut device-related complications vs transvenous systems (aHR 0.35) across 11,750 patients (Cardiology in Review).
- Cardiawave's Valvosoft noninvasive ultrasound therapy entered routine European clinical use for calcified AS leaflets in patients ineligible for SAVR or TAVR (Cardiovascular Business).
What to watch: Edwards Lifesciences Q2 earnings on July 23 against the backdrop of a fresh Medicare coverage proposal that pushed the stock to a 52-week high.
Aortic Valve (TAVR/TAVI)
[NOTABLE] A 10-year single-center series of 66 explants reports 22.2% operative mortality for early explants and 15.8% for late, with high-risk late explants reaching 41.2% — an observed-to-expected ratio of 2.81. Only 22.8% of late cases were isolated AVR; the rest required concomitant procedures. Three-year survival split sharply: 65.8% lower-risk vs 45.3% high-risk. The authors conclude that a TAVR-first strategy in younger and lower-risk populations warrants careful consideration — a conclusion in direct tension with ESC 2025's lowering of the TAVI-preferred threshold to age 70. ACC/AHA 2020 Class I favors SAVR below 65 on exactly these durability grounds, and today's data reinforces that position rather than undermining it. When TAVR fails in a younger patient, the salvage operation carries mortality that no index-procedure risk model fully captures.
Three procedural papers complete the picture. Self-expanding TAVR for non-calcified AR achieved 84% 12-month survival but 20% device migration requiring bailout — an off-label use that ESC 2025 rates Class IIb only for inoperable patients; SAVR remains the standard for operable AR regardless of age. CIDs patients showed equivalent mortality but higher vascular complications (10.3% vs 6.1%). OCEAN-TAVI data confirm that hemodialysis itself is not the prognostic driver after propensity matching — comorbidity burden is.
Mitral Valve (MitraClip, PASCAL, TMVR)
Extensive grasping with PASCAL does not compromise safety. A 391-patient single-center series compared ≤7 vs ≥8 grasping attempts (max 22) and found zero single leaflet device attachments, leaflet injuries, or device-related complications in either group. Procedures with ≥8 attempts ran 43 minutes longer and started with larger EROAs (0.48 vs 0.40 cm²), but MR reduction at discharge and at median 434-day follow-up was comparable. Mortality 7.3% vs 6.5%. Operators should not abandon difficult anatomy prematurely on safety grounds. The surgical comparator remains relevant: both ACC/AHA 2020 and ESC 2025 position MV repair as the gold standard for primary MR when a durable result is expected, with TEER Class IIa reserved for high-risk symptomatic patients — a distinction this single-center series, however reassuring on safety, cannot dissolve.
A 430-patient AVR series found that untreated mild-to-moderate MR at isolated SAVR progressed to ≥moderate MR in 5% at 1 year, driven by baseline moderate MR (OR 11.9), LA dimension, and AV peak velocity, with measurable composite-endpoint harm. The case for concomitant mitral intervention deserves a harder look in this subgroup. A robotic MitraClip prototype cut delivery time from 146.6s to 76.2s and positioning error from 3.1mm to 0.6mm in a phantom — a preclinical signal only, with no clinical translation data available.
Tricuspid Valve (TriClip, TTVR)
[NOTABLE] The first-in-man report of EVOQUE TTVR after prior Cardioband annuloplasty in an ARVC patient with ICD and NYHA IV symptoms is a window into where the field is heading: a 56-mm valve achieved immediate reduction from grade V to grade 0 TR, but the post-procedural course required prolonged mechanical ventilation, RRT for AKI, and ventricular arrhythmia management. Procedural success does not equal an uncomplicated course in advanced RV disease.
The delirium data sharpens the warning. TTVR carried a 4.4% delirium rate with an adjusted in-hospital mortality OR of 27.7 — the highest signal across all structural procedures studied in the National Inpatient Sample analysis. Frailty, dementia, and malnutrition were the strongest predictors. ESC 2025 elevated transcatheter TR therapy to Class IIa, LOE A based on TRILUMINATE, Tri.Fr, and TRISCEND II; ACC/AHA 2020 carries no recommendation because those trials had not read out. The indication is expanding — but the population most likely to receive transcatheter TR treatment is precisely the population at highest delirium risk, and that overlap demands prospective frailty screening before case acceptance.
Surgical vs. Transcatheter Comparisons
ACC reporting highlights that TAVR vs SAVR outcomes differ by sex and over time — consistent with the durability divergence emerging beyond 5 years. Today's explant series provides the rest of the equation: when TAVR fails in a younger patient, the salvage operation is not equivalent to a first-time SAVR. ACC/AHA 2020 Class I SAVR below 65 and ESC 2025 Class I SAVR below 70 (if low surgical risk) remain the anchor, and today's data does not weaken either position.
Device & Technology
[NOTABLE] Cardiawave's Valvosoft entered routine European clinical use after CE mark in late 2025. The noninvasive ultrasound technology fragments leaflet calcium in severe symptomatic AS for patients ineligible for SAVR or TAVR. The 100-patient pivotal study presented at EuroPCR 2025 showed feasibility, safety, and functional improvement. An IDE application for U.S. entry is planned. This is the first credible third option in symptomatic AS — neither replacement nor palliation — and it targets exactly the population guidelines have struggled with: inoperable but symptomatic patients with prognosis under 12 months who do not benefit from TAVI.
The leadless pacemaker meta-analysis (11,750 patients, 11 studies) showed aHR 0.35 for device-related complications vs transvenous systems post-TAVR, with comparable mortality and HF hospitalization. Given the persistent 10-15% pacemaker rate after TAVR, this is a meaningful procedural refinement.
Clinical Trial Updates
A 116-patient machine learning analysis identified iron deficiency (low ferritin and TSAT) as independent predictors of AKI within 48 hours after TAVI — a modifiable preprocedural target. Single-center, retrospective, small sample; the SHAP-based model achieved 96% sensitivity. A 492-patient surgical AVR registry showed that hemoglobin, creatinine, hsTrop-I, INR, CRP, NT-proBNP, and WBC each independently predict 30-day mortality after adjustment for EuroSCORE-II, and biomarker-augmented models outperformed EuroSCORE-II alone. Both findings sharpen Heart Team risk stratification.
Industry & Market
Edwards Lifesciences hit a 52-week high on the back of a Medicare coverage proposal, per MSN reporting. The bovine pericardial valve market is projected to reach $6.08B per openPR — a tailwind for both EW and the surgical valve makers. Today's TAVR explant data, if it gains traction, supports continued investment in surgical bioprosthetic platforms as the explant fallback.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $87.36, +0.78% on the day; 6-month +1.98%; near 52-week high of $89.60
- Market cap $50.3B; trailing P/E 47.22; forward P/E 25.94; beta 0.87
- Analyst target $96.92 (range $84–$110, 26 analysts); consensus Buy
- Next earnings July 23 (EPS est $0.74, revenue $1.70B)
EW touched a 52-week high this week following a Medicare coverage proposal. The pure-play structural heart story remains intact, and the SAPIEN franchise continues to dominate the TAVR conversation. Today's TAVR explant data is a long-term watch item, not a Q2 catalyst.
Medtronic (MDT)
- Close: $79.34, +1.54% on the day; 6-month -18.30%
- Market cap $101.9B; trailing P/E 21.05; forward P/E 12.38; beta 0.60
- Analyst target $98.00 (range $78–$121, 26 analysts); consensus Buy
- Next earnings August 18 (EPS est $1.39, revenue $9.55B)
MDT has been the laggard of the group at -18% over six months. The Evolut FX figured prominently in today's Japanese acute leaflet obstruction case report and the AR off-label series. Valuation at 12x forward looks defensive if the structural heart business stabilizes.
Abbott (ABT)
- Close: $88.41, -0.10% on the day; 6-month -28.72%
- Market cap $154.0B; trailing P/E 24.76; forward P/E 14.59; beta 0.62
- Analyst target $116.54 (range $92–$135, 24 analysts); consensus Buy
- Next earnings July 16 (EPS est $1.28, revenue $12.53B)
Abbott owns the MitraClip and TriClip franchises. Today's PASCAL grasping-attempts paper is a competitive data point — Boston Scientific's device shows safety with extensive manipulation. The broader ESC 2025 elevation of TEER for ventricular SMR to Class I remains the macro tailwind.
Boston Scientific (BSX)
- Close: $45.29, +0.76% on the day; 6-month -52.63%
- Market cap $67.3B; trailing P/E 18.95; forward P/E 12.16; beta 0.56
- Analyst target $77.10 (range $55–$106, 30 analysts); consensus Strong Buy
- Next earnings July 29 (EPS est $0.83, revenue $5.38B)
BSX is down 52% over six months despite Strong Buy consensus — the widest disconnect between analyst targets and price in the group. PASCAL safety data today supports the franchise. The Acurate neo platform remains the smaller TAVR position.
Anteris Technologies (AVR.AX)
- Close: A$13.32, -2.06% on the day; 6-month +75.26%
- Market cap A$1.3B; forward P/E -6.11; beta 0.73; 52-week range A$4.68–$13.85
- Single-analyst target A$13.00
The DurAVR single-piece bioprosthetic remains the long-shot story in next-generation TAVI durability. Six-month +75% reflects continued enthusiasm ahead of clinical data readouts.
The structural heart sector is bifurcating. EW commands premium pure-play multiples and is benefiting from CMS tailwinds. MDT, ABT, and BSX are trading at 12-15x forward earnings — discount territory for businesses with structural heart franchises positioned to benefit from ESC 2025's aggressive expansion of TEER and transcatheter TR indications. Today's TAVR explant data is the durability counterweight that could matter at the next ACC/AHA update.
Tomorrow's watch: any commentary from Edwards ahead of the July 23 earnings call on the durability question, and additional Valvosoft European real-world data that could pressure the inoperable-AS segment of the TAVR market.